Annexon (ANNX) to Post Quarterly Earnings on Thursday

Annexon (NASDAQ:ANNX) is anticipated to announce its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.23) per share and revenue of $6.50 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:00 PM ET.

Annexon (NASDAQ:ANNX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.07. On average, analysts expect Annexon to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Annexon Trading Up 0.8%

Shares of NASDAQ ANNX opened at $5.37 on Thursday. Annexon has a 1-year low of $2.03 and a 1-year high of $7.18. The company has a 50-day moving average of $5.35 and a two-hundred day moving average of $5.56. The company has a market cap of $879.82 million, a PE ratio of -4.40 and a beta of 1.18.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $14.00 price target on shares of Annexon in a report on Monday, July 20th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a report on Monday, July 13th. Citizens Jmp began coverage on Annexon in a research report on Tuesday, July 21st. They issued a “market underperform” rating and a $3.00 price objective on the stock. Citigroup assumed coverage on Annexon in a research note on Tuesday, July 21st. They issued a “market underperform” rating for the company. Finally, Wall Street Zen downgraded Annexon from a “hold” rating to a “sell” rating in a research report on Sunday, July 12th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $15.33.

Insider Activity at Annexon

In other Annexon news, Director Muneer A. Satter purchased 613,497 shares of the stock in a transaction dated Thursday, May 28th. The stock was bought at an average price of $5.41 per share, for a total transaction of $3,319,018.77. Following the transaction, the director directly owned 10,342,134 shares in the company, valued at $55,950,944.94. This represents a 6.31% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director William H. Carson acquired 8,000 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average price of $5.78 per share, for a total transaction of $46,240.00. Following the completion of the acquisition, the director directly owned 78,405 shares of the company’s stock, valued at $453,180.90. This trade represents a 11.36% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.31% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. CIBC Bancorp USA Inc. acquired a new stake in shares of Annexon during the third quarter worth $31,000. Engineers Gate Manager LP acquired a new position in Annexon in the second quarter valued at about $32,000. Landscape Capital Management L.L.C. bought a new position in Annexon during the fourth quarter worth about $50,000. Mercer Global Advisors Inc. ADV bought a new position in Annexon during the fourth quarter worth about $52,000. Finally, Russell Investments Group Ltd. acquired a new position in shares of Annexon during the 3rd quarter worth about $56,000.

Annexon Company Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.